Innovative pharmaceutical sector continues to surge, driving related ETFs to rise with it.

Recently, innovative drugs, especially the Hong Kong stock innovative drug sector, have continued to rise significantly, driving related ETFs to new heights and dominating the fund performance rankings. Data shows that as of May 30, Huatai-PineBridge Hang Seng Innovative Drug ETF, Invesco Hong Kong Stock Connect Innovative Drug ETF, and E Fund Hong Kong Stock Innovative Drug ETF have increased by 42.84%, 42.56%, and 41.88% respectively since the beginning of the year, ranking the top three in ETF performance so far this year. In addition, Wanjia Hong Kong Stock Innovative Drug ETF and GF Hong Kong Stock Innovative Drug ETF have also seen gains of over 40% since the beginning of the year. Meanwhile, actively managed innovative drug thematic funds have seen a sharp rebound after years of dormancy. As of May 29, Changcheng Medical Industry Selection and Everbright Medical Innovation Selection have surged by 64.42% and 55.34% respectively since the beginning of the year, ranking high in the fund performance rankings. Additionally, funds such as ICBC Great Health and ICBC Hong Kong Stock Connect Healthcare have also seen gains of over 50% since the beginning of the year. However, on June 2nd, the Hong Kong stock innovative drug sector experienced a significant adjustment, with Kangmei Biotech falling over 10% and Junshi Biosciences, Fosun Pharma, and others also experiencing declines of over 5%.